Vol.27/No.3

Sandip P. Patel, MD, discusses how AI can be used to improve clinical trial design and accrual.

Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.

Maurie Markman, MD, discusses the role of the individual vs the multidisciplinary team in cancer care.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.

Experts discuss the latest advancements in early lung cancer screening, including biomarkers and technologies that enhance detection and patient outcomes.